Abstract 5353: PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

奥西默替尼 PTEN公司 癌症研究 PI3K/AKT/mTOR通路 肺癌 克拉斯 蛋白激酶B 突变 医学 肿瘤科 生物 细胞凋亡 遗传学 基因
作者
Ursula Grazini,Daniel O'Neill,Matthew J. Martin,Chintia Xu,Nicolas Floc'h,Pete Smith,Emanuela M. Cuomo
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5353-5353
标识
DOI:10.1158/1538-7445.am2022-5353
摘要

Abstract Osimertinib is a third-generation EGFR-TKI approved for the first-line treatment of EGFR-driven lung adenocarcinomas. High response rates to osimertinib are observed in patients with activating EGFR mutations. However, there is variability in duration of response and patients eventually develop acquired resistance.Preclinical validation of potential acquired resistance mutations identified in relapsed patients treated with osimertinib is a key challenge to develop new strategies to improve outcomes for patients with EGFR mutation positive NSCLC. Tissue and ctDNA NGS analysis from relapsed patients treated first-line with osimertinib in the FLAURA and ORCHARD trials identified PIK3CA gain of function (GOF 11%) and PTEN loss of function (LOF 5%) mutations.To test whether PIK3CA activating mutations can drive resistance to osimertinib we introduced PIK3CA activating variants (PIK3CA-H1047R and PIK3CA-E453K) or knocked-out PTEN in NSCLC lung cancer cell lines harbouring EGFR activating mutations and WT PIK3CA/PTEN using CRISPR/Cas9 technology. Our results show that PIK3CA GOF and PTEN LOF mutations conferred resistance to osimertinib in vitro. Resistance was associated with increased EC50 for osimertinib and diminished apoptotic response in NSCLC PIK3CA GOF and PTEN LOF mutant CRISPR cell lines when compared to parental cells. Protein analysis by western blot also showed an increase in the basal and osimertinib treated levels of pAKT and pS6 in PIK3CA/PTEN CRISPR engineered cell lines, indicating activation of downstream PI3K/AKT and MAPK signalling pathways in the osimertinib-resistant cells. Importantly, our in vitro experiments from multiple cell line models indicated that PIK3CA-mediated resistance to osimertinib could be partially reversed by co-treatment with AKT (capivasertib, AstraZeneca) and PI3K alpha (alpelisib, Novartis) inhibitors; PTEN-mediated resistance could be rescued by co-treatment with capivasertib and PI3K beta (AZD8186, AstraZeneca) inhibitors. We next examined the in vivo efficacy of osimertinib + AKT/PI3K inhibitors therapies in NSCLC xenograft models. Our in vivo analysis show that PIK3CA GOF CRISPR engineered cells displayed diminished response to osimertinib when implanted in mice; importantly, combination with AKT (capivasertib) or PI3K alpha (alpelisib) inhibitors enhanced response on treatment and delayed outgrowth after withdrawal treatment. In addition, we observed that combination treatment with capivasertib induced tumour stasis in a PIK3CA-E454K and two PTENloss PDX models.Altogether our in vitro and in vivo data provide evidence of PIK3CA mutants and PTEN loss-driven mechanisms of resistance to osimertinib and offer possible therapeutic combination strategies for those patients that develop resistance or experience a sub-optimal response to osimertinib through PIK3CA/PTEN mutations Citation Format: Ursula Grazini, Daniel J. O'Neill, Matthew Martin, Chintia Xu, Nicolas Floch, Paul D. Smith, Emanuela Cuomo. PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5353.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
1秒前
1秒前
1秒前
lmei完成签到 ,获得积分10
1秒前
贾贾发布了新的文献求助10
1秒前
1秒前
FashionBoy的应助被王少雄采纳,获得10
2秒前
zxe发布了新的文献求助10
2秒前
WZJ发布了新的文献求助10
2秒前
烧鸭饭发布了新的文献求助10
2秒前
2秒前
磨磨完成签到,获得积分10
3秒前
轻松的立果完成签到,获得积分10
3秒前
gao完成签到 ,获得积分10
3秒前
白白发布了新的文献求助10
3秒前
wsg发布了新的文献求助30
4秒前
袁志阳发布了新的文献求助10
4秒前
lily发布了新的文献求助10
4秒前
蔡蔡小星发布了新的文献求助10
5秒前
小姜完成签到,获得积分10
5秒前
一路生花发布了新的文献求助10
5秒前
情怀的应助被木东采纳,获得10
5秒前
5秒前
Rachel_1219完成签到,获得积分10
6秒前
6秒前
充电宝的应助被爱笑的小豁牙采纳,获得10
6秒前
赵琪发布了新的文献求助10
7秒前
俊逸老太发布了新的文献求助10
7秒前
鹤轩完成签到,获得积分10
7秒前
拼搏梦安发布了新的文献求助10
7秒前
隐形曼青的应助被雪雪儿采纳,获得10
7秒前
糖心发布了新的文献求助10
7秒前
小猪熊完成签到,获得积分10
7秒前
芒果完成签到,获得积分10
7秒前
8秒前
桐桐的应助被绝非仅仅采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460